Overview

Randomized Trial of Beta-Carotene and Macular Degeneration

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982. To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E. To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake.
Phase:
Phase 3
Details
Lead Sponsor:
National Eye Institute (NEI)
Treatments:
Aspirin
Beta Carotene
Carotenoids